“This might suggest that if we decrease systemic inflammation in the body we can decrease the risks of these serious comorbidities,” he said.
In a follow-up call, Dr. Evans said that a limitation of the study is its retrospective design. “We (the National Psoriasis Foundation) are looking forward to developing a psoriasis registry and are in partnership with the rheumatoid arthritis registry and corrona.org. We hope to enroll tens of thousands of psoriasis patients nationally in the voluntary registry. This will be a boon to looking at these correlations.”
